Pharmacogenomics
Pharmacogenomics is a respected peer-reviewed journal that features articles and reports from researchers and key decision-makers who are actively engaged in this fast-evolving field. Its main aim is to serve as a vital resource for those wanting to stay updated on the latest advancements in pharmacogenomics. The journal primarily emphasizes topics that are highly relevant to the pharmaceutical industry and the broader clinical community, including: - The rise of new pharmacogenomic projects and their influence on research and development, as well as regulatory approaches - Innovative technologies that facilitate the use of genomic data - Reviews of genotyping and clinical findings in specific treatment areas - The creation of new diagnostic tools and strategies Pharmacogenomics stands out as a premier source for expert insights and analysis, offering high-quality commentary from leading figures in both corporate and academic circles in the field.
Outlet metrics
Global
#5939045
United States
#2960968
Health/Medicine
#9849
Articles
-
May 16, 2024 |
futuremedicine.com | Mohamed Kamal |Mohamed Nagy |Omneya Hassanain
The application of personalized medicine in developing countries is a major challenge, especially for those with poor economic status. A critical factor in improving the application of personalized medicine is the efficient allocation of resources. In healthcare systems, optimizing resource allocation without compromising patient care is paramount. This tutorial employs a simulation-based approach to evaluate the efficiency of bed allocation within a hospital setting.
-
May 5, 2024 |
futuremedicine.com | Di Jiang |Abhijat Kitchlu |Launay-Vacher V |Richard T O'Dwyer
RT O'Dwyer has received support for travel and attending meetings from Pfizer and research funding from EMD Serono. DM Jiang has received research funding from Amgen, Tersera, and Astellas Pharma; honoraria from Janssen Oncology, Ipsen, Bayer, EMD Serono, Amgen, and AstraZeneca; consulting fees from Bayer, Pfizer, EMD Serono, McKesson, AstraZeneca, Merck, Janssen Oncology, and Novartis AAA; and support for attending meetings from EMD Serono. A Kitchlu administers funding from Amgen and Janssen.
-
May 2, 2024 |
futuremedicine.com | Laura Durbin |Bhavna Murali |Stephanie Hawthorne |Otávio Clark
Lung cancer is the most common form of cancer in China, with approximately 900,000 new cases diagnosed each year [1]. It is also the deadliest cancer in this country, with approximately 24% of all cancer deaths in China attributed to lung cancer [2].
-
May 2, 2024 |
futuremedicine.com | Emma Guttman-Yassky |Laura Brooks |Ken Clark |Lila Bahadori
This is an abstract of the Plain Language Summary of Publication article. To read the full Plain Language Summary of this article, click here to view the PDF. Link to original article hereAcknowledgmentsWe thank the patients and their caregivers, as well as the study investigators and site staff, for participating in this study. We thank Olivia Fulton for providing feedback on the readability of this publication.
-
Apr 30, 2024 |
futuremedicine.com | Yan Zhang |Bing Luo
Papers of special note have been highlighted as:• of interest; •• of considerable interest• None , Viral causality of human cancer and potential roles of human endogenous retroviruses in the multi-omics era: an evolutionary epidemiology review . ;11:687631. doi: . English. • A total of seven viruses have been found to cause tumors in humans. ;11:687631. doi:. English. • A total of seven viruses have been found to cause tumors in humans.
Contact details
Address
123 Example Street
City, Country 12345
Phone
+1 (555) 123-4567
Email Patterns
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →